CA3213127A1 - Derivatives of amphotericin b - Google Patents

Derivatives of amphotericin b

Info

Publication number
CA3213127A1
CA3213127A1 CA3213127A CA3213127A CA3213127A1 CA 3213127 A1 CA3213127 A1 CA 3213127A1 CA 3213127 A CA3213127 A CA 3213127A CA 3213127 A CA3213127 A CA 3213127A CA 3213127 A1 CA3213127 A1 CA 3213127A1
Authority
CA
Canada
Prior art keywords
alkyl
compound
cycloalkyl
group
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3213127A
Other languages
English (en)
French (fr)
Inventor
Martin D. Burke
Arun P. Thottumkara
Kevin T. Mellem
Zachary K. Sweeney
Elena S. Koltun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elion Therapeutics Inc
Original Assignee
Sfunga Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sfunga Therapeutics Inc filed Critical Sfunga Therapeutics Inc
Publication of CA3213127A1 publication Critical patent/CA3213127A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
CA3213127A 2015-04-15 2016-04-15 Derivatives of amphotericin b Pending CA3213127A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562147949P 2015-04-15 2015-04-15
US62/147,949 2015-04-15
CA3021061A CA3021061C (en) 2015-04-15 2016-04-15 Derivatives of amphotericin b

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA3021061A Division CA3021061C (en) 2015-04-15 2016-04-15 Derivatives of amphotericin b

Publications (1)

Publication Number Publication Date
CA3213127A1 true CA3213127A1 (en) 2016-10-20

Family

ID=57126898

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3213127A Pending CA3213127A1 (en) 2015-04-15 2016-04-15 Derivatives of amphotericin b
CA3021061A Active CA3021061C (en) 2015-04-15 2016-04-15 Derivatives of amphotericin b

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3021061A Active CA3021061C (en) 2015-04-15 2016-04-15 Derivatives of amphotericin b

Country Status (7)

Country Link
US (3) US9957290B2 (enExample)
EP (2) EP3929203A1 (enExample)
JP (3) JP7240811B2 (enExample)
CA (2) CA3213127A1 (enExample)
ES (1) ES2880029T3 (enExample)
PT (1) PT3283171T (enExample)
WO (1) WO2016168568A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102548341B1 (ko) 2013-10-07 2023-06-26 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 개선된 치료 지수를 갖는 암포테리신 b 유도체
MX378786B (es) 2014-06-12 2025-03-11 Shionogi & Co Derivado de macrólido de polieno.
PT3283171T (pt) * 2015-04-15 2021-07-14 Sfunga Therapeutics Inc Derivados de anfotericina b
WO2017100171A1 (en) * 2015-12-08 2017-06-15 Kalyra Pharmaceuticals, Inc. Antifungal compounds and methods
WO2018106571A1 (en) * 2016-12-06 2018-06-14 Kalyra Pharmaceuticals, Inc. Antifungal compounds and methods
CN113056274A (zh) * 2018-09-07 2021-06-29 伊利诺伊大学评议会 具有降低的毒性的杂化两性霉素b衍生物
EP4009984A4 (en) * 2019-08-08 2023-09-06 The Board Of Trustees Of The University Of Illinois HYBRID AMPHOTERICIN B DERIVATIVES WITH REDUCED TOXICITY
AU2020325163B2 (en) * 2019-08-08 2026-04-23 The Board Of Trustees Of The University Of Illinois Hybrid amide derivatives of amphotericin B
FR3112145A1 (fr) * 2020-07-03 2022-01-07 Nanotracks Diagnostics Derives uree de macrolides polyeniques, composes chimiques particuliers susceptibles d’etre utilises pour obtenir ces derives uree, compositions les contenant et utilisations
WO2022003181A1 (fr) * 2020-07-03 2022-01-06 Nanotracks Diagnostics Derivés urée de l'amphotéricine amb, compositions les contenant et leurs utilisations, dérivés isocyanate d'alkyle omega-aminés et leur utilisation pour obtenir lesdits dérivés urée
AU2021325676A1 (en) * 2020-08-10 2023-03-30 The Board Of Trustees Of The University Of Illinois Hybrid amide derivatives of amphotericin B

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0350164A3 (en) * 1988-06-13 1991-07-24 Beecham Group Plc Amphotericin derivatives
GB8829592D0 (en) 1988-12-19 1989-02-08 Beecham Group Plc Novel compounds
EP0431870A1 (en) 1989-12-08 1991-06-12 Beecham Group p.l.c. Amphotericin B derivatives
JP3507486B2 (ja) 1991-03-15 2004-03-15 アムジエン・インコーポレーテツド 顆粒球コロニー刺激因子の肺内投与
GB9203476D0 (en) 1992-02-19 1992-04-08 Smithkline Beecham Plc Novel compounds
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
US5606038A (en) 1995-04-10 1997-02-25 Competitive Technologies, Inc. Amphiphilic polyene macrolide antibiotic compounds
PL180253B1 (pl) * 1995-05-13 2001-01-31 Politechnika Gdanska Pochodne N-metylo-N-glikozylowe estrów metylowych antybiotyków z grupy makrolidów polienowych i ich sole oraz sposób ich otrzymywania PL PL PL PL PL PL
US6664241B2 (en) 2000-05-31 2003-12-16 Micrologix Biotech Inc. Water-soluble amide derivatives of polyene macrolides and preparation and uses thereof
US20090186838A1 (en) * 2006-02-23 2009-07-23 Eidgenössische Technische Hochschule Zürich Amphotericin Derivatives
JP5240704B2 (ja) * 2007-10-05 2013-07-17 国立大学法人群馬大学 新規蛍光化合物およびそれを用いた細胞内コレステロールの検出方法
JP2015519389A (ja) 2012-06-15 2015-07-09 ブリート スポルカ アクシヤ 抗真菌性抗生物質アンフォテリシンｂのｎ−置換第二世代誘導体ならびにそれらの調製および塗布方法
WO2014165676A1 (en) 2013-04-03 2014-10-09 The Board Of Trustees Of The University Of Illinois Amphotericin b derivative with reduced toxicity
KR102548341B1 (ko) * 2013-10-07 2023-06-26 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 개선된 치료 지수를 갖는 암포테리신 b 유도체
WO2015164289A1 (en) * 2014-04-21 2015-10-29 Cidara Therapeutics, Inc. Compositions and methods for the treatment of fungal infections
JP6543272B2 (ja) 2014-05-16 2019-07-10 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイＴｈｅ Ｂｏａｒｄ Ｏｆ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｉｌｌｉｎｏｉｓ 低減された毒性を有するアンホテリシンｂ誘導体
MX378786B (es) * 2014-06-12 2025-03-11 Shionogi & Co Derivado de macrólido de polieno.
WO2016014779A1 (en) 2014-07-23 2016-01-28 The Board Of Trustees Of The University Of Illinois Antifungal polyene macrolide derivatives with reduced mammalian toxicity
WO2016040779A1 (en) 2014-09-12 2016-03-17 The Board Of Trustees Of The University Of Illinois Urea derivatives of polyene macrolide antibiotics
ES3072651T3 (en) 2014-10-17 2026-07-03 Univ Illinois Scalable synthesis of reduced toxicity derivative of amphotericin b
JP6726192B2 (ja) 2015-01-08 2020-07-22 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイＴｈｅ Ｂｏａｒｄ Ｏｆ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｉｌｌｉｎｏｉｓ アムホテリシンｂの尿素誘導体の簡便な合成法
WO2016112243A1 (en) 2015-01-08 2016-07-14 The Board Of Trustees Of The University Of Illinois Urea derivatives of amphotericin b derived from secondary amines
PT3283171T (pt) * 2015-04-15 2021-07-14 Sfunga Therapeutics Inc Derivados de anfotericina b

Also Published As

Publication number Publication date
PT3283171T (pt) 2021-07-14
EP3929203A1 (en) 2021-12-29
HK1244248A1 (zh) 2018-08-03
EP3283171A4 (en) 2019-03-13
EP3283171A1 (en) 2018-02-21
EP3283171B1 (en) 2021-05-26
US10597420B2 (en) 2020-03-24
US10882883B2 (en) 2021-01-05
WO2016168568A1 (en) 2016-10-20
CA3021061C (en) 2023-10-24
JP2021075570A (ja) 2021-05-20
CA3021061A1 (en) 2016-10-20
US20180273572A1 (en) 2018-09-27
ES2880029T3 (es) 2021-11-23
US9957290B2 (en) 2018-05-01
JP7240811B2 (ja) 2023-03-16
US20160304548A1 (en) 2016-10-20
JP2018514522A (ja) 2018-06-07
JP2023030103A (ja) 2023-03-07
US20200262858A1 (en) 2020-08-20

Similar Documents

Publication Publication Date Title
US10882883B2 (en) Derivatives of amphotericin B
US10836750B1 (en) TLR7/8 antagonists and uses thereof
CA3110474C (en) Highly active sting protein agonist compound
JP7794736B2 (ja) エキノカンジン類似体及びその調製方法
AU2021201355B2 (en) Seco macrolide compounds
SK13972001A3 (sk) Erytromycínové deriváty
AU2019335409B2 (en) Hybrid amphotericin B derivatives with reduced toxicity
EP3774843B1 (en) Dipeptide piperidine derivatives
HK1244248B (en) Derivatives of amphotericin b
JP2003532625A (ja) ストレプトグラミン誘導体、それらの製造およびそれらを含有する組成物
HK40048031A (en) Highly active sting protein agonist compound

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231214

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250219

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250219

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250219

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250326

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20250728

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260527

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260703